Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease

American Journal of Cardiology

Volumn 79, Issue 5 A, 1997, Pages 17-23

  Selwyn, Andrew P ^a   Kinlay, Scott ^a   Creager, Mark ^a   Libby, Peter ^a   Ganz, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; PROTEIN KINASE C;

ARTERY INTIMA; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PATHOGENESIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0031004546     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00125-2     Document Type: Conference Paper

References (106)

1. Gotto MA, Farmer JA. Risk factors for coronary artery disease. In: Braunwald E, ed. Heart: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1988:1153-1167.
2. Cox DA, Cohen ML. Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Pharmacol Rev 1996;48:3-18.
3. Davis J. Anatomic features in victims of sudden death. Coronary artery pathology. Circulation 1992;85:119-124.
4. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle content. Br Heart J 1993;69:377-381.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering therapy in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
6. Shepherd J, Cobbe SM, Isles CG, Lorimer AR, MacFarlane PN, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
7. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
8. Meredith IT, Yeung AC, Weidinger FF, Anderson TJ, Uehata A, Ryan TJ Jr, Selwyn AP, Ganz P. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993; 87(suppl V):V-56-V-66.
9. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051.
10. Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993;88:43-54.
11. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-497.
12. Gordon JB, Ganz P, Nabel EG, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis and endothelial function influence the coronary vasomotor response to exercise. J Clin Invest 1989;83:1946-1952.
13. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991;325:1551-1556.
14. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changes in blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990;16:349-356.
15. Brown G, Alberts JJ, Fisher LD. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
16. Fuster V, Badimon JJ. Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Eur Heart J 1995;16(suppl E):6-12.
17. MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993;22:1228-1241.
18. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;81:3883-3887.
19. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984;4:357-364.
20. Zhanu H, Banka HJK, Steinbrecher UP. Effects of oxidatively modified LDL on cholesterol esterification in cultured macrophages. J Lipid Res 1990;31:1361-1369.
21. Steinbrecher UP. Oxidation of human low density lipoprotein results in esterification of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987;262:3605-3608.
22. Fruehis J, Parthasarathy S, Steinberg D. Evidence for concerted reaction between lipid hydroperoxides and polypeptides. Proc Natl Acad Sci USA 1992;89:10588-10592.
23. Yla-Herticala S, Palinski W, Rosenfeld ME, Parthamakathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-1095.
24. Salunen JT, Yia-Herttuala S, Yamamoto H, Butler S, Korpela H, Salonen R, Nyyasonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-887.
25. Cazzolato G, Avogaro P, Bittolo-Bon G. Characterization of a more electronegatively charged LDL subfraction by ion exchange HPLC. Free Radic Biol Med 1991;11:247-253.
26. Daugherty A, Zweefel BS, Sobel BE, Schonfeld G. Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis 1988;8:768-777.
27. Hirata K, Kuroda R, Sakoda T, Katayama M, Inoue N, Suematsu M, Kawashima S, Yokoyama M. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 1995;25:180-185.
28. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokohama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995;76:958-962.
29. Furchgott RF, Zawadzski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
30. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
31. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
32. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992;89:6348-6352.
33. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol 1995;369:39-48.
34. Tanner FC, Noll G, Boulanuk CM, Lüscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary artery: role of scavenger receptor and endothelium-derived nitric oxide. Circulation 1991;83:2012-2020.
35. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 1990;86:75-79.
36. Yokohama M, Hirata K, Miyake R, Akita H, Ishikawa Y, Fukuzari H. Lysophosphalidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. Biochem Biophys Res Commun 1990;169:301-308.
37. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-162.
38. Kugiyama K, Ohgushi M, Sugiyama S, Mukohara T, Fukunaga K, Miyamoto E, Yasue H. Lysophosphatidylcholine inhibits surface receptor mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res 1992;71:1422-1428.
39. Harrison DG. Endothelial function in atherosclerosis. Basic Res Cardiol 1994;89(suppl 1):87-102.
40. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature 1986;320:454-456.
41. Seccombe JF, Pearson PJ, Schaff HV. Oxygen radical-mediated vascular injury selectively inhibits receptor-dependent release of nitric oxide from canine coronary arteries. J Thorac Cardiovasc Surg 1994;107:505-509.
42. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995;270:319-324.
43. Ohara Y, Sayegh HS, Yamin JJ, Harrison DG. Regulation of endothelial constitutive nitric oxide synthase by protein kinase C. Hypertension 1995;25:415-420.
44. 1α subunit expression by oxidized low-density lipoprotein. J Clin Invest 1995;95:1457-1463.
45. Ahmad M, Marui N, Alexander RW, Medford RM. Cell type-specific transactivation of the VCAM-1 promoter through an NF-kappa B enhancer motif. J Biol Chem 1995;270:8976-8983.
46. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995;95:1262-1270.
47. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmand M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-1874.
48. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988;77:43-52.
49. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989;80:458-465.
50. Vita JA, Treasure CB, Yeung AC, Vekshtein VI, Fantasia GM, Fish RD, Ganz P, Selwyn AP. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992;85:1390-1397.
51. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-1474.
52. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994;24:471-476.
53. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-234.
54. Dyce MC, Anderson TJ, Yeung AC, Ganz P, Lieberman EH, Gerhard MD, Selwyn AP, Meredith IT. Indices of LDL particle size closely related to endothelial dysfunction. (Abstr.) Circulation 1993;88(No. 4, pt 2):466.
55. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994;89:2525-2532.
56. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest 1995;95:1747-1755.
57. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88(No. 5, pt 1):2149-2155.
58. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996;334:150-154.
59. McFadden EP, Clarke JG, Davies GJ, Kaski JC, Haider AW, Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991;324:648-654.
60. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986;73:865-876.
61. Seiler C, Suter TM, Kess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol lowering drug therapy with bezafibrate. JAm Coll Cardiol 1995;26:1615-1622.
62. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-1500.
63. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
64. Treasure CB, Klein JL, Weintraub WS, Alexander W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
65. Anderson TJ, Meredith IT, Yeung AC, Charbonneau F, Selwyn AP, Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-1650.
66. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 1995;346:467-471.
67. Tamai O, Matsuoka H, Nishida H, Itabe H, Wada Y, Kohno K, Nomura G, Imaizumi T. Single LDL-apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation (in press).
68. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992;90:1138-1144.
69. Rajavarhisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusib AJ. Induction of endothelial expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-357.
70. Collins T, Read MA, Neigh AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NFB and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
71. Rosenkranz-Weiss P, Sessa WC, Milstien S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells; elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest 1994;93:2230-2245.
72. Simari RD, San H, Rekhter M, Ohno T, Gordon D, Nabel GJ, Nabel EG. Regulation of cellular proliferation and intimai formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 1996;98:225-235.
73. Wilcox JN. Analysis of local gene expression in human atherosclerotic plaque. J Vasc Surg 1992;15:913-916.
74. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1991;11:1223-1230.
75. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
76. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995;15:1512-1531.
77. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(suppl 2):II-38-II-46.
78. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-1338.
79. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850.
80. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
81. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 1995;748:501-507.
82. Libby P, Galis ZS. Cytokines regulate genes involved in atherogenesis. Ann NY Acad Sci 1995;748:158-168.
83. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis: implications for plaque rupture. Arterioscler Thromb Vasc Biol 1996;16:1070-1073.
84. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25(suppl 2):S9-S12.
85. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-521.
86. Harrison DG. Endothelial function in atherosclerosis. Basic Res Cardiol 1994;89(suppl 1):87-102.
87. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987;80:1808-1811.
88. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 1995;270:17050-17055.
89. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995; 270:14214-14219.
90. Shin WS, Hong YH, Peng HB, De Caterina R, Libby P, Liao JK. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma: the role of constitutive NF-kappa B activity. J Biol Chem 1996;271:11317-11324.
91. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelial-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987;92:181-187.
92. Holvoel P, Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J 1995;8:1279-1284.
93. Shireman PK, McCarthy WJ, Pearce WH, Patterson BK, Shively VP, Cipollone M, Tamarina N, Verrusio EN, Kwaan HC. Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta. J Vasc Surg 1996;23:810-817.
94. Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996;16:539-545.
95. Amman V, Nilsson A, Stemme S, Risberg B, Rymo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb Res 1994;76:487-499.
96. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995;74:626-630.
97. Cherchi GM, Coinu R, Demuro P, Formato M, Sanna G, Tidmore M, Tira ME, DeLuca G. Structural and functional modifications of human aorta proteoglycans in atherosclerosis. Biochim Biophys Acta 1994;1212:345-352.
98. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995;76(suppl C):24C-33C.
99. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-1569.
100. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 1995;92:1701-1709.
101. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354-1363.
102. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
103. McLenachan JM, Weidinger FF, Barry J, Yeung A, Nabel EG, Rocco MB, Selwyn AP. Relations between heart rate, ischemia, and drug therapy during daily life in patients with coronary artery disease. Circulation 1991;83:1263-1270.
104. Andrews TC, Raby K, Barry J, Naimi C, Allred E, Ganz P, Selwyn AP. Effects of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-328.
105. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latin R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-1538.
106. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJGM, Lie KI, Bruschke AVG, on behalf of the REGRESS Study Group. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996;94:1503-1505.